Summary Since 2004, dermatologists have been using several biologics for inflammatory skin diseases: omalizumab for chronic spontaneous urticaria, dupilumab for atopic dermatitis and more than 10 different biologics and biosimilars for chronic plaque psoriasis. These anti-psoriasis biologics are very effective in moderate to severe forms of psoriasis and show at least a 75% reduction in PASI (PASI 75). At present an anti-IL-17a therapy offers the greatest chance to reach PASI 90. The longest median drug survival of a biologic is for ustekinumab (38.0 months), followed by adalimumab (36.5 months). For female patients of childbearing age and pregnant patients certolizumab has become available. Because of the extensive choice regarding biologics in psoriasis, it can be difficult to make exactly the right choice for a patient with moderate to severe chronic plaque psoriasis.

Biologics, Biosimilars, Clinical efficacy, Drug survival, Psoriasis, Safety profile
hdl.handle.net/1765/131846
Nederlands Tijdschrift voor Dermatologie en Venereologie
Erasmus MC: University Medical Center Rotterdam

Thio, H.B. (2018). Door het bos de biologische bomen niet meer zien. Nederlands Tijdschrift voor Dermatologie en Venereologie, 28(10), 27–30. Retrieved from http://hdl.handle.net/1765/131846